Although mRNA technology is still relatively new, its potential to treat a wide variety of diseases is promising, and companies like Moderna are at the forefront of the development of this technology.
Moderna doesn’t seem to be slowing down. The biotech giant has announced their latest project, and they’re not just targeting the evolving H5N1 virus. We’re talking about tick-borne Lyme disease and the notorious “stomach flu,” norovirus. Forbes writes that Moderna is considering strengthening its pipeline and expanding its offerings as demand for Covid-19 vaccines begins to wane.
In focus. Technology emerged telegraph channel. Subscribe to not miss the latest and most interesting news from the world of science!
Tick-borne Lyme disease is a bacterial infection spread by the bite of an infected tick. If left untreated, it can cause flu-like symptoms, joint pain, and even serious long-term health problems.
Norovirus is a highly contagious virus that can cause inflammation of the stomach and intestines, causing symptoms such as nausea, vomiting and diarrhea. It’s often called the “stomach flu,” but it’s not related to the flu virus.
It hasn’t been an easy road for Moderna – it took years to get mRNA technology into production. But as soon as the pandemic hit, the company hit the jackpot with its Covid vaccine. Now that things have slowed down, Moderna feels the need to diversify. All kinds of vaccines are under development, from respiratory diseases such as Covid, influenza and RSV to genetic conditions and infectious diseases such as HIV, herpes simplex virus and cytomegalovirus.
Moderna has big plans, with six “essential vaccines” coming out in the next few years. And they’re not just sharing theoretical plans, they already have an RSV vaccine that they expect to receive regulatory approval this quarter. However, they delayed the flu vaccine a bit, arguing that more data needed to be collected.
Now for the money – Moderna estimates the global market for Covid booster vaccines at $15 billion per year. They hope to generate up to $9 billion in sales of respiratory products, including Covid booster vaccines and potential future vaccines for diseases like RSV. That’s a lot of money folks.
Previously Focus He wrote about the return to the Middle Ages. The global cholera situation has worsened since 16 December 2022, when the outbreak was first reported.
Source: Focus
Ashley Fitzgerald is an accomplished journalist in the field of technology. She currently works as a writer at 24 news breaker. With a deep understanding of the latest technology developments, Ashley’s writing provides readers with insightful analysis and unique perspectives on the industry.